Accept Cookies

Cookies: We use cookies on our website to make it clear, useful and reliable. This includes storing a small amount of data about you. By navigating to other sections of our website, you are consenting to information being stored. Find out more here.

Coronavirus: Stay alert, protect the NHS, save lives... Find our Covid-19 information and updates here >
National services

Our experts

National services

Our experts

National services

Our experts

National services

Our experts

Prof Sir Robin Murray

Professor of Psychiatric Research and Consultant Psychiatrist


Area of expertise
  • Psychosis
  • Schizophrenia
  • Bipolar disorder
  • Drug-induced psychosis

Biography
Robin Murray is Professor of Psychiatric Research at the Institute of Psychiatry, Psychology and Neuroscience, Kings College, and indeed has spent most of his working life there apart from one year at NIMH in the USA.

He was one of the first to suggest that schizophrenia was in part a neurodevelopmental disorder, and he and his colleagues have contributed to the understanding that environmental factors such as obstetric events, drug abuse and social adversity dysregulate striatal dopamine and thus increase the risk of psychosis.

He also cares for people with psychosis at the Trust. He has written over 800 articles and is the most frequently cited psychosis researcher outside the USA. He has supervised 72 PhDs and 12 MD Theses, and 40 of his students have become full professors. He was elected a Fellow of the Royal Society in 2010 and received a knighthood in 2011.

Education and training
  • MBChB University of Glasgow 1968
  • MRCP 1974
  • MD Univ of Glasgow 1974
  • MRCPsych 1976
  • DSc 1988 London University

Selected publications
Dempster, E.L., Pidsley, R., Schalkwyk, L.C., …… Murray, R.M., Mill, J. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Human Molecular Genetics. 2011, 20(24), 416, pp. 4786-4796

Demjaha, A., Murray RM McGuire, P.K., Kapur, S., Howes, O.D. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. American Journal of Psychiatry 2012, 169(11), pp. 1203-1210

Englund A, Morrison PD, Nottage J, … Murray RM, Kapur S. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of Psychopharmacology, 2013, 27 (1), 19-27

Schizophrenia Working Group of the Psychiatric Genomics Consortium (Ripke S, Neale BM, Corvin, A, … Murray RM, et al). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 2014, 511 (7510), 421-427

Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet, 2014,383 (9929), 1677-1687

Di Forti M, Marconi A, Carra E, … Murray R. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry, 2015, 2 (3): 233-238

Kahn R, Schizophrenia. Kahn, R.S., Sommer, I.E., Murray, R.M., Weinberger D, Van Os, J., Insel, T.R. Nature Neuroscience. 2015, 19(4), pp. 571-577

Howes, O.D., McCutcheon, R., Owen, M.J., Murray, R.M. The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. Biological Psychiatry 2016, 81(1), pp. 9-20

Lally J,Ajnakina O, Di Forti M……..Murray RM. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological Medicine. 2016,46:3231-3240. Epub 2016 Sep 8.

Di Forti, M, Quattrone, D, …….Murray,RM. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study Lancet Psychiatry 2019; 6: 427–36